A trial comparing ceritinib with chemotherapy for advanced non small cell lung cancer (ASCEND 4)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Lung cancer
Non small cell lung cancer
Secondary cancers

Status:

Results

Phase:

Phase 3

This trial looked at how well ceritinib worked for people whose non small cell lung cancer had changes to a protein called ALK. This is called ALK positive non small cell lung cancer (NSCLC).

It was for people having their first treatment for advanced lung cancer.

More about this trial

When researchers began this trial, the usual treatment for non small cell lung cancer that has spread elsewhere in the body (advanced cancer) was chemotherapy. This included a platinum drug Open a glossary item such as cisplatin or carboplatin. Some people may also have had a targeted cancer drug. But not everyone responded well to these treatments.  

Researchers are looking for new targeted cancer drugs to treat advanced NSCLC. In this trial, they looked at a drug called ceritinib.

Changes to the gene Open a glossary item called anaplastic lymphoma kinase (ALK) can send signals to cancer cells telling them to grow. Ceritinib (LDK378 or Zykadia) is a cancer growth blocker. It blocks the ALK gene and stops it sending growth signals to cancer cells, which may stop them growing.

The aims of this trial were to:

  • find out how well ceritinib works for advanced NSCLC compared to chemotherapy
  • find out more about quality of life Open a glossary item 
  • learn more about the side effects

Summary of results

The trial team found that ceritinib improved the length of time people lived without signs of their cancer getting worse. 

This phase 3 trial took place worldwide. 376 people took part. People were put into 1 of the following 2 treatment groups at random.

  • 189 people had ceritinib capsules once a day
  • 187 people had the chemotherapy drug pemetrexed with either cisplatin or carboplatin (standard treatment at the time the trial began)

ASCEND 4

Neither they nor their doctor could choose which group they were in. 

People who had 4 cycles of chemotherapy without their cancer getting worse continued to have pemetrexed to keep the cancer away for longer. This is called maintenance treatment.

Everyone had treatment for as long as it worked and the side effects weren’t too bad. They had regular scans to see if treatment was working. In this trial, people having chemotherapy could start having ceritinib if their cancer got worse. 80 people who stopped chemotherapy went on to have ceritinib.

The trial team looked at the average length of time people lived without signs of their cancer getting worse. Researchers call this progression free survival. They found this was:

  • 16.6 months in people who had ceritinib
  • 8.1 months in people who had chemotherapy 

ASCEND 4

In both treatment groups, most of the side effects were mild. People having ceritinib had more problems with:

  • diarrhoea
  • feeling or being sick
  • an increase in an enzyme Open a glossary item in the liver called ALT

People having chemotherapy had more problems with a drop in the number of red blood cells causing tiredness and breathlessness. This is called anaemia. Although they also had some problems with feeling or being sick. 

Everyone taking part completed regular questionnaires which looked at the symptoms and side effects they had and how this was affecting their day to day life. This is called quality of life. They found that people having ceritinib reported a better quality of life and an improvement in lung cancer symptoms such as pain, cough and shortness of breath. 

The researchers did this analysis in 2016. They also planned to look at the number of people alive. This is called overall survival. But it was too early to interpret this data as there wasn’t enough information available. The trial team are still following up those who took part so they hope to have the overall survival results in February 2022.

The trial team concluded that ceritinib worked for people with ALK positive non small cell lung cancer. It improved the length of time people lived without signs of their cancer getting worse. The side effects weren’t too serious and most people reported an improvement in quality of life.  

We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Dr Raffaele Califano

Supported by

NIHR Clinical Research Network: Cancer
Novartis

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

11220

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think